title: Inhibition of skin tumor initiation, promotion, and progression by antioxidants and related compounds.
abstract: Antioxidants have been shown to inhibit the induction of cancer by a wide variety of chemical carcinogens and radiation at many target sites in mice, rats, hamsters, and man. Evidence is accumulating that suggests that free radicals are important in all stages of chemical carcinogenesis. Both carcinogens and tumor promoters have also been shown to decrease the cellular activity of superoxide dismutase and catalase. A number of antioxidants and related compounds were tested to determine if they would inhibit either skin tumor initiation, promotion, or progression. In terms of skin tumor initiation, compounds such as BHT, vitamins E and C, and CuDIPS have been found to inhibit DMBA skin tumor initiation. The mechanism of action of these compounds appears to be related to their effect on the metabolism of DMBA, as BHT and CuDIPS do not inhibit the initiating activity of BP-diol-epoxide and MNNG. Although several antioxidants do inhibit skin tumor initiation by procarcinogens, antioxidants are in general much more effective inhibitors of skin tumor promotion. BHT, BHA, parahydroxyanisole, disulfiran, and vitamins E and C as well as many other antioxidants are very effective inhibitors of skin tumor promotion. We also determined the effect of free radical scavengers on the progression process. Of the agents tested, glutathione and N-acyl dehydroalamines were the most effective in reducing carcinoma incidence. Diethyl maleate, a chemical that reduces glutathione levels, was effective in enhancing progression. In addition, overexpression of gamma-glutamyltranspeptidase (GGT), which leads to a reduction in cellular glutathione levels, also enhances progression.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: University of Texas, M. D. Anderson Cancer Center, Science Park--Research Division, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Slaga
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D002374:Catalase / Q000378:metabolism; D006224:Cricetinae; D006801:Humans; D051379:Mice; D051381:Rats; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000975:Antioxidants; D015127:9,10-Dimethyl-1,2-benzanthracene; D002374:Catalase; D013482:Superoxide Dismutase